Join Growin Stock Community!
Beta
Back to NVO.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • P/E Ratio
  • P/S Ratio
  • P/B Ratio
  • EV/EBITDA
  • EV/Sales
  • PE Ratio River
pe-stream-chart

NVO PE Ratio River

PE Ratio River

Browsing restrictions can be lifted for a fee.

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

## NVO PE Stream Chart Analysis As of the latest data point (mid-March 2026), NVO's monthly average price stands at approximately **$37.45**, which has fallen **below the lowest PE boundary of 1.6 times** (priced at ~$37.44). This places the stock firmly in the **Undervalued** zone — the most deeply discounted valuation tier on the PE stream chart. The current price is well beneath the 2.7 times boundary (~$62.02), the 3.8 times boundary (~$86.59), the 4.8 times boundary (~$111.40), the 5.9 times boundary (~$135.98), and the 7.0 times boundary (~$160.55). This extreme positioning signals that NVO is trading at historically compressed valuations relative to its earnings, representing a significant departure from where the stock was priced just 12–18 months ago. Historically, NVO's valuation trajectory tells a dramatic story of expansion followed by sharp contraction. From early 2021 through mid-2024, the stock climbed steadily through the PE bands — beginning in the **Fair** zone (between 3.8 times and 4.8 times) and progressively advancing into the **Watch** and **Overvalued** zones. The stock reached its peak valuation around mid-2024, when prices briefly approached or touched the **7.0 times (Warning)** boundary near ~$138–$139, reflecting peak investor enthusiasm — likely tied to the GLP-1/obesity drug boom. From late 2024 onward, however, the price began a sustained and steep decline, retreating through each PE band in succession. By late 2025 and into early 2026, the stock broke below the 2.7 times **Value** zone and ultimately collapsed beneath the 1.6 times **Undervalued** threshold. Notably, the PE stream bands themselves have continued to trend upward throughout this period, suggesting that the company's underlying earnings have remained on a growth trajectory — making the current price compression even more pronounced. This divergence between rising PE boundaries and a falling stock price indicates a significant valuation de-rating, warranting close attention from investors evaluating long-term entry opportunities.